Methods of treating traumatic encephalopathy syndrome
Rho kinase inhibitors, particularly fasudil, offer a promising treatment for Traumatic Encephalopathy Syndrome by enhancing cognitive and neurobehavioral functions in patients with repetitive head trauma, effectively addressing the lack of effective therapies for TES by improving MMSE scores and reducing symptom severity.
Patent Information
- Application Number
- PCT/US2024/029409
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
Current therapeutic approaches are ineffective for treating Traumatic Encephalopathy Syndrome (TES), a condition associated with repetitive brain trauma, leading to cognitive and neurobehavioral impairments, with no disease-modifying treatments available.
Administration of a rho kinase inhibitor, specifically an isoquinoline derivative like fasudil, to patients with a history of repetitive head impacts, which improves cognitive and neurobehavioral functions by reducing symptom severity and delaying progression of TES symptoms.
The treatment with rho kinase inhibitors, such as fasudil, leads to significant improvements in cognitive function, as measured by MMSE scores, and alleviates neurobehavioral symptoms like aggression and depression, with improved MMSE scores ranging from 5 to 10 points, and reduced symptom progression.
Smart Images

Figure IMGF000005_0001 
Figure IMGF000006_0001 
Figure IMGF000007_0001
Abstract
Citation Information
Patent Citations
4-haloisoquinoline derivative and drug containing the same
US20070088021A1
Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof
US20080194581A1
Isoquinolin-3-yl carboxamides and preparation and use thereof
US20220332698A1
Oral formulations of fasudil with ion exchange resin
US20230330101A1
Methods of treating proteinopathies
WO2022015365A1
